BioWorld

April 26, 2006

DOV Shares Crushed After Phase III Bicifadine Failure

Poor Phase III data nearly halved DOV Pharmaceutical Inc.'s stock value Tuesday after the findings were unveiled late Monday. (BioWorld Today) Read More

Millipore Paying $1.4B In Cash To Buy Serologicals

Discovery Lab's Stock Crashes On News Of Surfaxin Problem

Light Sciences Oncology Files To Raise $86M In IPO

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Flow Neuro wins FDA nod for at-home device for depression

BioWorld MedTech

Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...